April 25 (Reuters) - Sanofi's Sasy.pa Said on Thursday First-Quarter Operating Income Declined 14.7% as Unfavourable Currency Effects and Cheap Competition to Multiple Sclerosis Drug Aubagio Outweighed Rising Sales of Anti-Inflammatory Drug Dupixent.
4月25日（路透社）——赛诺菲 Sasy.pa 周四表示，由于不利的货币影响和对多发性硬化症药物Aubagio的廉价竞争超过了抗炎药物Dupixent的销售增长，第一季度营业收入下降了14.7％。
The French Drugmaker Said in a Statement That Operating Income, Adjusted for One-Offs, Slipped 14.7% to 2.84 Billion Euros ($3.04 Billion), a Touch Above the 2.79 Billion Euros Expected on Average by Analysts in a Poll on the Company's Website.
这家法国制药商在一份声明中表示，经一次性调整后的营业收入下降了14.7％，至28.4亿欧元（合30.4亿美元），略高于分析师在该公司网站上进行的一项民意调查中预期的平均27.9亿欧元。
The Company Reiterated It Expects 2024 Adjusted Earnings per Share (EPS) to Slip by a "Low Single-Digit" Percentage, Excluding Currency Swings, Citing Higher Taxes and an Increase in Development Expenditure.
该公司重申，预计2024年调整后的每股收益（EPS）将下降 “较低的个位数” 百分比，其中不包括货币波动，理由是税收增加和发展支出增加。
Currency Changes Would Drag 2024 Earnings Lower by Between 5.5% and 6.5% at Current Rates, It Added.
它补充说，按当前利率计算，货币变化将使2024年的收益下降5.5％至6.5％。
($1 = 0.9338 Euros)
（$1 = 0.9338 欧元）
(Reporting by Ludwig Burger; Editing by Benoit Van Overstraeten)
（路德维希·伯格报道；Benoit Van Overstraeten编辑）
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))